relatlimab

Home
Ligands
relatlimab

GtoPdb Ligand ID: 9536

Synonyms: BMS-986016 | BMS986016 | ONO-4482 | Opdualag® (nivolumab + relatlimab-rmbw) | relatlimab-rmbw

relatlimab is an approved drug (EMA & FDA (2022))

Comment: Relatlimab (BMS-986016) is an anti-LAG3 monoclonal antibody that was developed for utility in cancer immunotherapy.

References
1. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI et al.. (2004) Role of LAG-3 in regulatory T cells. Immunity, 21 (4): 503-13. [PMID:15485628]
2. Lonberg N, Srinivasan M. (2014) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof. Patent number: WO2014008218. Assignee: Bristol-Myers Squibb Company. Priority date: 02/07/2012. Publication date: 09/01/2014.
3. Nguyen LT, Ohashi PS. (2015) Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol, 15 (1): 45-56. [PMID:25534622]
4. Fully human monoclonal antibody specific for lymphocyte activation gene 3 and nivolumab. Accessed on 21/09/2017. Modified on 21/09/2017. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=595017

References

1. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI et al.. (2004)
Role of LAG-3 in regulatory T cells.
Immunity, 21 (4): 503-13. [PMID:15485628]

2. Lonberg N, Srinivasan M. (2014)
Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof.
Patent number: WO2014008218. Assignee: Bristol-Myers Squibb Company. Priority date: 02/07/2012. Publication date: 09/01/2014.

3. Nguyen LT, Ohashi PS. (2015)
Clinical blockade of PD1 and LAG3--potential mechanisms of action.
Nat Rev Immunol, 15 (1): 45-56. [PMID:25534622]

4. Fully human monoclonal antibody specific for lymphocyte activation gene 3 and nivolumab.
Accessed on 21/09/2017. Modified on 21/09/2017. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=595017